Thus, BCL2 and other members of the BCL2 family of proteins have been reported to be overexpressed in AML and correlate with resistance to cytotoxic chemotherapy and to targeted agents (Kornblau et al, 1999; Mehta et al, 2013). This evidence concerns the gene BCL2 and acute myeloid leukemia.